Clinical Trial Update: Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating atezolizumab with or without chemotherapy for locoregional MSI-H/dMMR gastric and gastroesophageal junction cancers; the study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Status: ACTIVE_NOT_RECRUITING